Advertisement

April 16, 2020

Proximo Medical Named Commercialization Partner for Elucid Bioimaging

April 16, 2020—Proximo Medical, LLC, announced a partnership with Elucid Bioimaging, a developer of diagnostic image analysis software used to assist in the detection and treatment of heart attack and stroke.

Proximo Medical is a business-acceleration company that addresses medical device commercialization challenges among startup and established medical device technologies looking to expand adoption in the United States. Proximo Medical provides market analysis, economic insights, access to key thought leaders, and a sales and marketing team focused on commercial execution.

According to the announcement, Elucid Bioimaging vascuCAP is an FDA-cleared, histologically validated software for evaluation of atherosclerotic plaque stability from a single CT angiography to inform the risk of a cardiovascular event and treatment selection. The technology uses machine learning to analyze CT scans of arteries and automatically quantify and classify the type of atherosclerotic plaque to accurately predict events, inform optimal intervention, and guide preprocedural planning.

Blake Richards, CEO of Elucid Bioimaging, commented, “VascuCAP helps cardiologists, vascular surgeons, and radiologists determine the right intervention for the right patient to a level of specificity that existing noninvasive diagnostics cannot detect.”

Advertisement


April 16, 2020

SCAI Position Statement Addresses Training for Treatment of Adult Congenital Heart Disease

April 13, 2020

Pooled Analysis Shows Substantial Long-Term MACE Risk After PCI for Stable Ischemic Heart Disease